PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers
Leisl Packer(Translational Research Institute), Pamela M. Pollock(Queensland University of Technology)
Cited by 51
Related Papers
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
|Molecular Cancer Research|2009|118
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
|Molecular Cancer|2012|45
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models
|Journal of Cell Science|2018|25